Publications

Register to Read

October 2000 (Revised June 2017)
Case

Vyaderm Pharmaceuticals: The EVA Decision

By: Robert Simons and Indra A. Reinbergs

In 2016, the new CEO of Vyaderm Pharmaceuticals introduces an Economic Value Added (EVA) program to focus the company on long-term shareholder value. The EVA program consists of three elements: EVA centers (business units), EVA drivers (operational practices that... View Details

Keywords: Compensation and Benefits; Employee Relationship Management; Economic Growth; Economic Systems; Management; Motivation and Incentives; Organizational Design; Organizational Structure; Performance Evaluation; Decision Choices and Conditions; Pharmaceutical Industry; Washington (state, US)

March 2014 (Revised December 2014)
Case

Vision 2020: Takeda and the Vaccine Business

By: John A. Quelch and Margaret L. Rodriguez

In 2014, Yasuchika Hasegawa was orchestrating the transformation of Takeda from a Japanese pharmaceutical company with a global footprint into a global company with a Japanese heritage. A 33-year veteran of Takeda, Hasegawa-san was appointed president of Takeda in 2003... View Details

Keywords: Health Care; Global; NGO; Public Health; Japan; GSK; Vaccine; Supply Chain; Market Entry; Health; Health Care and Treatment; Trade; Market Entry and Exit; Global Strategy; Pharmaceutical Industry; Pharmaceutical Industry

February 2007 (Revised April 2010)
Case

Wyeth Pharmaceuticals: Spurring Scientific Creativity with Metrics

By: Robert S. Huckman, Gary P. Pisano and Mark Rennella

Describes the reorganization of the drug discovery organization at Wyeth Pharmaceuticals and focuses on the decisions to: (1) centralize decision-making within drug discovery and (2) institute numerical metrics--jointly affecting all R&D scientists--for the progression... View Details

Keywords: Decision Making; Measurement and Metrics; Business Processes; Organizational Structure; Research and Development; Science-Based Business; Creativity; Pharmaceutical Industry

January 1993 (Revised April 1993)
Case

Chadwick, Inc.: The Balanced Scorecard

By: Robert S. Kaplan

The pharmaceutical division of a diversified company has been asked to develop a Balanced Scorecard. Research and development projects take about ten years to bring a new product to the marketplace and the division depends on good relations and active feedback from its... View Details

Keywords: Balanced Scorecard; Performance Evaluation; Customer Relationship Management; Goals and Objectives; Customer Satisfaction; Research and Development; Marketplace Matching; Financial Condition; Product Launch; Pharmaceutical Industry

September 2013 (Revised February 2016)
Case

GlaxoSmithKline: Sourcing Complex Professional Services

By: Heidi K. Gardner and Silvia Hodges Silverstein

Pharmaceutical company GlaxoSmithKline (GSK) uses an innovative new approach to procuring outside legal counsel: it replaces relationship-based selection and law firms' traditional time-based billing with data-driven decision making and an online reverse auction. In... View Details

Keywords: Legal Industry; Procurement; Professional Service Firms; Pricing; Competition; Change Management; Supply Chain Management; Legal Liability; Business Processes; Pharmaceutical Industry; Pharmaceutical Industry

03 May 2022
News

Q&A With Harvard Business School Professor Linda A. Hill

August 2008 (Revised September 2008)
Supplement

The Flaxil Label (C): Debrief and Endnotes

This case focuses on the 2001 negotiation between Mytex Pharmaceuticals and the U.S. Food and Drug Administration (FDA). The outcome of the negotiation would determine the new label for Mytex's blockbuster drug for arthritis, Flaxil. The negotiation is quite... View Details

Keywords: Safety; Value Creation; Negotiation; Health Care and Treatment; Sales; Pharmaceutical Industry

September 1991 (Revised February 1993)
Case

Burroughs Wellcome and AZT (A)

By: Willis M. Emmons III

Burroughs Wellcome Co., developer of AZT, the first drug approved by the U.S. Food and Drug Administration for the treatment of Acquired Immune Deficiency Syndrome (AIDS), finds itself under siege in September 1989 by AIDS activists and various segments of the U.S.... View Details

Keywords: Governing Rules, Regulations, and Reforms; Ethics; Business and Government Relations; Communication Strategy; Health Care and Treatment; Monopoly; Intellectual Property; Research and Development; Price; Pharmaceutical Industry; London

May 2014
Article

Right Up the Middle: How Israeli Firms Go Global

By: Jonathan Friedrich, Amit Noam and Elie Ofek

The article considers international business enterprises based in Israel and how they successfully expanded from their origins as small businesses. A common technique of those companies in which they focused on market entry in other countries whose markets were too... View Details

Keywords: Globalized Firms and Management; Israel

Find at Harvard

Read Now

August 2008 (Revised September 2008)
Case

The Flaxil Label (A)

This case focuses on the 2001 negotiation between Mytex Pharmaceuticals and the U.S. Food and Drug Administration (FDA). The outcome of the negotiation would determine the new label for Mytex's blockbuster drug for arthritis, Flaxil. The negotiation is quite... View Details

Keywords: Governing Rules, Regulations, and Reforms; Health Disorders; Product Launch; Negotiation Process; Business and Government Relations; Safety; Pharmaceutical Industry

February 2010
Case

Real Blue? Viagra and Intellectual Property Rights Law in China

By: Regina M. Abrami and Tracy Manty

On July 5, 2004, Pfizer's China team received disappointing news. China's patent review board just invalidated the company's existing patent on one of its most successful drugs, Viagra. Making matters worse, a Guangdong-based pharmaceutical company laid claim to... View Details

Keywords: Trade; International Relations; Patents; Trademarks; Lawsuits and Litigation; Rights; Business and Government Relations; Pharmaceutical Industry; China

October 2023 (Revised June 2024)
Case

Catalent: Catalyzing the Next Era of Growth

By: Satish Tadikonda, William Marks and Kevin Emancipator

Catalent's newly appointed CEO, Alessandro Maselli, experienced the highs of the pharmaceutical contract development manufacturing (CDMO) space during COVID-19 while helping Moderna and others bring vaccines to market quickly and safely. After rushing to add capacity... View Details

Keywords: Leadership; Business or Company Management; Organizational Change and Adaptation; Pharmaceutical Industry

27 Sep 2011
First Look

First Look: September 27

specificity at the individual level. We discuss the implications of our results for the study of learning and experience as well as for the providers and consumers of outsourced services. Download the paper: http://www.hbs.edu/research/pdf/11-057.pdf U.S. Healthcare... View Details

Keywords: Sean Silverthorne

August 2001
Case

Finnigan Corporation

By: Carliss Y. Baldwin and Barbara Feinberg

Finnigan Corp., headquartered in San Jose, CA, was the world's leading producer of mass spectrometers, holding a 45% market share of instruments used for chemical analysis in pharmaceutical product development, environmental testing, genetic testing, and other... View Details

Keywords: Business Exit or Shutdown; Financial Crisis; Machinery and Machining; Technology Industry; San Jose